Furthermore, the RAAS system may have a direct role in complement pathway activation through renin-mediated C3 cleavage as demonstrated in vitro and suggested through a study evaluating the efficacy of direct renin inhibition (aliskiren) in dense deposit disease where reduced systemic and renal complement activation was observed [37]. This evidence concerns the gene REN and dense deposit disease.